APG Asset Management N.V. Purchases New Shares in Solventum Co. (NYSE:SOLV)

APG Asset Management N.V. bought a new stake in Solventum Co. (NYSE:SOLV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,563 shares of the company's stock, valued at approximately $546,000.

Several other hedge funds also recently bought and sold shares of the company. New York Life Investment Management LLC raised its position in Solventum by 0.7% during the fourth quarter. New York Life Investment Management LLC now owns 18,506 shares of the company's stock valued at $1,223,000 after acquiring an additional 136 shares in the last quarter. Blue Trust Inc. lifted its stake in shares of Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company's stock valued at $549,000 after purchasing an additional 161 shares during the last quarter. MML Investors Services LLC increased its position in Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock worth $373,000 after buying an additional 168 shares during the last quarter. Avantax Advisory Services Inc. raised its holdings in Solventum by 2.2% during the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company's stock valued at $584,000 after buying an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Solventum by 48.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company's stock worth $45,000 after buying an additional 223 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SOLV. Bank of America boosted their target price on Solventum from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Wednesday, February 26th. Wells Fargo & Company boosted their target price on shares of Solventum from $73.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Friday, February 28th. The Goldman Sachs Group lifted their price objective on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Piper Sandler raised their target price on Solventum from $75.00 to $84.00 and gave the company a "neutral" rating in a report on Friday, February 28th. Finally, Morgan Stanley increased their price objective on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $79.86.

Solventum Price Performance

SOLV stock traded up $0.56 during trading on Friday, hitting $66.23. The company had a trading volume of 910,263 shares, compared to its average volume of 1,325,909. The company has a market cap of $11.46 billion and a P/E ratio of 24.08. The company has a fifty day moving average price of $73.56 and a two-hundred day moving average price of $71.62. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.